hrcak mascot   Srce   HID

Kratko priopćenje

Parkinson’s Disease – Challenges in New Drug Development

Tomislav Babić
Darija Mahović

Puni tekst: engleski, pdf (79 KB) str. 1275-1281 preuzimanja: 394* citiraj
APA 6th Edition
Babić, T. i Mahović, D. (2008). Parkinson’s Disease – Challenges in New Drug Development. Collegium antropologicum, 32 (4), 1275-1281. Preuzeto s https://hrcak.srce.hr/34443
MLA 8th Edition
Babić, Tomislav i Darija Mahović. "Parkinson’s Disease – Challenges in New Drug Development." Collegium antropologicum, vol. 32, br. 4, 2008, str. 1275-1281. https://hrcak.srce.hr/34443. Citirano 20.09.2020.
Chicago 17th Edition
Babić, Tomislav i Darija Mahović. "Parkinson’s Disease – Challenges in New Drug Development." Collegium antropologicum 32, br. 4 (2008): 1275-1281. https://hrcak.srce.hr/34443
Harvard
Babić, T., i Mahović, D. (2008). 'Parkinson’s Disease – Challenges in New Drug Development', Collegium antropologicum, 32(4), str. 1275-1281. Preuzeto s: https://hrcak.srce.hr/34443 (Datum pristupa: 20.09.2020.)
Vancouver
Babić T, Mahović D. Parkinson’s Disease – Challenges in New Drug Development. Collegium antropologicum [Internet]. 2008 [pristupljeno 20.09.2020.];32(4):1275-1281. Dostupno na: https://hrcak.srce.hr/34443
IEEE
T. Babić i D. Mahović, "Parkinson’s Disease – Challenges in New Drug Development", Collegium antropologicum, vol.32, br. 4, str. 1275-1281, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/34443. [Citirano: 20.09.2020.]

Sažetak
Idiopathic Parkinson’s disease (IPD) is the second most common neurodegenerative disorder after Alzheimer’s disease.
Treatment aims in IPD include the provision of symptomatic relief, reduction of functional disability, halting or
slowing of the neurodegenerative process, and the prevention of long-term complications by proper initiation of therapy.
At present, pharmacotherapeutic strategies allow the amelioration of motor symptoms of IPD only, whereas non-motor
manifestations are not helped by dopamine replacement strategies. In addition, levodopa-induced fluctuation and dyskinesia
are still challenging, particularly in long-term treatment. Despite advances in pharmacotherapy that have improved
quality of life for these patients, the mortality rate remains largely unchanged. Sustained interest in IPD will
hopefully allow increased funding of research to develop new and better treatments.

Ključne riječi
Parkinson’s disease; therapy; levodopa; dopamine agonists

Hrčak ID: 34443

URI
https://hrcak.srce.hr/34443

Posjeta: 556 *